Oncofusion

start / graph / ana-yeats-asymmetry-tested-against-intron-geometry

Analysismoderate confidence 3 of 5: One strong study, or several smaller consistent ones.Q29-mllt3-yeats-loss

Is the YEATS asymmetry just intron geometry? Computed from hg38: the direction is explained, the magnitude is not, and both genes fail the same prediction

also called MLLT1 MLLT3 intron architecture · YEATS breakpoint geography

We measured how much DNA sits in each part of the two genes, to see whether AF9 loses its reader simply because there is far more DNA to break in the wrong place. The shape of the answer is right but the size is badly wrong, and in a way that says breaks are not scattered at random.

The same thing, for a scientist

The standing question behind this beat is whether MLLT1 retains its YEATS domain and MLLT3 discards it because of **functional selection** or **structural accident**. Exon and intron coordinates for both canonical RefSeq transcripts were pulled from hg38 on 2026-09-20 and the target zones computed. **The exon-to-residue mapping is identical in the two paralogues**: exon 1 encodes aa 1-4, exon 2 aa 5-64, exon 3 aa 65-92 and exon 4 aa 93-140 in both, so the YEATS domain occupies exons 1-4 of each gene and the comparison is exact. The intron lengths are not identical at all. **MLLT1 intron 1 is 9,013 bp; MLLT3 intron 1 is 1,410 bp** - a 6.4-fold smaller target for the one intronic break that preserves the whole reader. **MLLT3 intron 2 alone is 163,867 bp, 2.4 times the entire 69,595 bp MLLT1 gene.** Under uniform intronic breakage the predicted YEATS-preserving fraction is **13.9% for MLLT1 and 0.51% for MLLT3**, a 26.9-fold gap pointing exactly the way the patients do. So geometry explains the *direction* without invoking selection. It fails badly on a second prediction: uniform breakage predicts **partial** YEATS inclusion in 61.1% of intragenic MLLT1 breaks and 62.9% of MLLT3 breaks, against observed 14.8% and at most about 1.1% [E1]. **Both genes have a huge, cold 5-prime intron.** Breakage is therefore concentrated in the 3-prime introns in both paralogues, and intron length alone is not the mechanism.

Go deeper
Method, and why the comparison is exact

https://api.genome.ucsc.edu/getData/track?genome=hg38;track=ncbiRefSeqSelect was queried for chr19:6,100,000-6,300,000 and chr9:20,300,000-20,700,000 on 2026-09-20. The returned records are NM_005934.4 (MLLT1, chr19:6,210,380-6,279,975, minus strand, 12 exons) and NM_004529.4 (MLLT3, chr9:20,341,668-20,622,499, minus strand, 11 exons) 4. Exon blocks were ordered 5-prime to 3-prime by strand, introns computed between consecutive blocks, and coding lengths accumulated across the CDS to map each exon to residues.

The mapping came out identical for the two genes over the reader:

exonMLLT1 residuesMLLT3 residues
11-41-4
25-645-64
365-9265-92
493-14093-140

This independently reproduces the primary paper's statement that the ENL YEATS domain is coded from exons 2-4 (amino acids 5-140) 1, and extends it: AF9's YEATS domain has exactly the same exon structure, which is what makes an intron-length comparison meaningful rather than apples-to-oranges.

The intron lengths
intronMLLT1 (bp)MLLT3 (bp)
19,0131,410
28,268163,867
331,5148,437
43,46733,697
54,29247,976
64,0792,063
71,4402,634
82,3665,862
91411,211
103176,950
11166-
gene span69,595280,831

Grouped by what a break there does to the fusion's YEATS content:

zoneintronsMLLT1 (bp)MLLT3 (bp)
preserves the whole reader19,0131,410
partial reader2-339,782172,304
no reader4 onward16,268100,393
total intronic65,063274,107

Under breakage uniform in intronic length: MLLT1 gives 13.9% / 61.1% / 25.0% and MLLT3 gives 0.51% / 62.9% / 36.6%.

What it predicts right, and what it gets badly wrong

Right, and it is not a small thing. The predicted YEATS-preserving fraction differs 26.9-fold between the two genes (13.9% against 0.51%) purely because of where the DNA is. In a cohort of 442 t(9;11) patients, 0.51% predicts 2.3 patients; the observed number of YEATS-retaining MLL-AF9 patients is 2 1. That agreement is close enough to be a coincidence and is still the single most economical explanation on offer for the rarity of a YEATS-positive MLL-AF9.

Wrong, and this is the informative part. Uniform breakage predicts that the partial class should dominate both genes, because introns 2-3 are the largest zone in each. It does not:

predicted partialobserved partial
MLLT1 (intragenic breaks, n=149)61.1%14.8% (22/149)
MLLT3 (n=442)62.9%<=1.1% (at most ~5)

For MLLT1 the model over-predicts fourfold. For MLLT3 it over-predicts at least fiftyfold. In both genes the large 5-prime intron is cold, and the breaks pile up 3-prime of it.

And the model cannot see MLLT1's dominant break zone at all. 50.7% of t(11;19) patients break 5-prime of MLLT1 and 3-prime of ACER1 - outside the gene 1. No intronic model covers that, and it is the largest single class of MLL-ENL patients.

What this leaves standing

Three readings survive, and the entry's job is to say which the numbers discriminate.

  1. Structural accident, in a refined form. Not 'breaks are uniform and MLLT3 has more DNA', which fails, but 'each locus has a breakage hotspot region, and the hotspot sits 3-prime of the reader in MLLT3 and 5-prime of it in MLLT1'. This is consistent with every number above, including the cold 5-prime introns, and it is a claim about topoisomerase-II cleavage and chromatin rather than about protein function. It is testable without a single patient: map TOP2 cleavage in etoposide-treated haematopoietic cells across both loci and ask whether the hotspots sit where the patients' breaks do.
  2. Functional selection. AF9 YEATS suppresses transformation and ENL YEATS supports it, so the observed distributions are what survives. Nothing here refutes this, and the 2-patient agreement is weak evidence against it only because a selection model would predict zero, not two.
  3. Both. Geography sets the supply of breakpoints and selection filters them. Under this reading the MLLT1 partial class (22 patients, 7.3%) is the population that should be followed clinically, because it is the one place where the supply is large and the filter is visible.

What the numbers do not support is the framing this graph has carried, in which the asymmetry is treated as a fact about the proteins. A 6.4-fold difference in intron-1 length between two genes whose exon structure is otherwise identical is a fact about the DNA.

Facts and figures
statusrun
run date2026-09-20
model verdictDirection explained without selection; magnitude of the partial class mispredicted fourfold in MLLT1 and at least fiftyfold in MLLT3. Both genes have a cold 5-prime intron, so breakage is not uniform per base pair.
discriminating experimentmap topoisomerase-II cleavage across both loci in etoposide-treated haematopoietic cells and ask whether the hotspots sit where the patients' breaks do
observed PCT
MLLT1_all_n3028.600MLLT1_all_n302: 8.6MLLT1_intragenic_n14917.4MLLT1_intragenic_n149: 17.4MLLT3_n44298.4MLLT3_n442: 98.4
headline ratios
MLLT3_intron2_over_whole_…2.350MLLT3_intron2_over_whole_MLLT1_gene: 2.35intron1_length_ratio_MLLT…6.400intron1_length_ratio_MLLT1_over_MLLT3: 6.4predicted_preserve_ratio_…26.9predicted_preserve_ratio_MLLT1_over_MLLT3: 26.9
inputs
[
  "https://api.genome.ucsc.edu/getData/track?genome=hg38;track=ncbiRefSeqSelect;chrom=chr19;start=6100000;end=6300000",
  "https://api.genome.ucsc.edu/getData/track?genome=hg38;track=ncbiRefSeqSelect;chrom=chr9;start=20300000;end=20700000",
  "breakpoint distributions from PMID 36435883"
]
transcripts
{
  "MLLT1": "NM_005934.4 chr19:6,210,380-6,279,975 minus strand, 12 exons",
  "MLLT3": "NM_004529.4 chr9:20,341,668-20,622,499 minus strand, 11 exons"
}
exon to residue
{
  "exon1": "aa 1-4 in both",
  "exon2": "aa 5-64 in both",
  "exon3": "aa 65-92 in both",
  "exon4": "aa 93-140 in both"
}
introns bp
{
  "MLLT1": [
    9013,
    8268,
    31514,
    3467,
    4292,
    4079,
    1440,
    2366,
    141,
    317,
    166
  ],
  "MLLT3": [
    1410,
    163867,
    8437,
    33697,
    47976,
    2063,
    2634,
    5862,
    1211,
    6950
  ]
}
gene span bp
{
  "MLLT1": 69595,
  "MLLT3": 280831
}
zones bp
{
  "MLLT1": {
    "preserves_reader_intron1": 9013,
    "partial_reader_introns2_3": 39782,
    "no_reader_intron4_onward": 16268,
    "total_intronic": 65063
  },
  "MLLT3": {
    "preserves_reader_intron1": 1410,
    "partial_reader_introns2_3": 172304,
    "no_reader_intron4_onward": 100393,
    "total_intronic": 274107
  }
}
predicted under uniform intronic breakage PCT
{
  "MLLT1": {
    "preserve": 13.9,
    "partial": 61.1,
    "none": 25
  },
  "MLLT3": {
    "preserve": 0.51,
    "partial": 62.9,
    "none": 36.6
  }
}
observed PCT — the numbers behind the chart
{
  "MLLT1_all_n302": {
    "full": 84.1,
    "partial": 7.3,
    "none": 8.6,
    "note": "50.7 of the 84.1 is intergenic, 5-prime of MLLT1 and 3-prime of ACER1, i.e. outside any intron"
  },
  "MLLT1_intragenic_n149": {
    "preserve": 67.8,
    "partial": 14.8,
    "none": 17.4
  },
  "MLLT3_n442": {
    "preserve": 0.5,
    "partial": "<=1.1",
    "none": 98.4
  }
}
headline ratios — the numbers behind the chart
{
  "intron1_length_ratio_MLLT1_over_MLLT3": 6.4,
  "predicted_preserve_ratio_MLLT1_over_MLLT3": 26.9,
  "MLLT3_intron2_over_whole_MLLT1_gene": 2.35
}
How this could bite us back
  • If breakpoint position is set by cleavage geography rather than by selection, then 'the fusion discarded its reader' is not a designed property and there is no reason to expect restoring it to be informative about what the leukaemia needs - which weakens the rationale for the in-cis add-back experiment this graph proposes.
  • Therapy-induced t(9;11) is the largest therapy-induced KMT2A group, so any topoisomerase-II cleavage explanation of MLLT3 breakpoint geography is simultaneously a statement about how cytotoxic therapy creates this disease.
Still open
  1. Where does topoisomerase II actually cleave in MLLT1 and MLLT3 in haematopoietic cells? A published cleavage map over these two loci would settle the accident-versus-selection question more cheaply than any patient study.
  2. Are the unaccounted ~1.1% of the 442 t(9;11) patients partial-YEATS cases? That single number is the difference between the intron-length model failing fiftyfold and failing sixtyfold.
  3. Does any other KMT2A partner pair with near-identical exon structure and very different intron lengths exist, so that this comparison can be replicated rather than resting on one pair?
Every source behind this entry (4)
  1. E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper

    The ENL YEATS domain is coded from exons 2-4 (amino acids 5-140); 50.7% (n=153) of 302 t(11;19) patients break 5-prime of MLLT1 and 3-prime of ACER1, 33.4% (n=101) within MLLT1 intron 1, giving 84.1% (n=254) full YEATS retention, with 7.3% (n=22) partial inclusion and 8.6% (n=26) no inclusion; AF9 breaks fall downstream of MLLT3 exon 4 in 98.4% of 442 t(9;11) patients and only two (0.5%) break upstream of MLLT3 exon 1 and retain the YEATS domain.

    What this evidence cannot show

    Read verbatim from the PMC HTML body (PMC11246743) on 2026-09-20 after `fullTextXML` returned HTTP 500. Both distributions are re-analyses of a diagnostic referral archive, and the MLLT3 analysis is a supplementary figure in a paper about ENL. The residual ~1.1% of the 442 is not described, so the observed MLLT3 partial count is an upper bound of about 5, not a measurement.

    Evidence that argues against this (1)
    • If the unaccounted ~1.1% of t(9;11) patients are all partial-YEATS cases, the observed MLLT3 partial fraction is 1.1% rather than 0%, which changes the size of the model's failure but not its sign - the prediction is 62.9%. Hu H et al. 2023
  2. E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper

    Breakpoint distributions within KMT2A itself are not uniform and shift with age, disease and fusion partner, with breakpoints in MLL intron 11 associated with ALL and younger patients and intron 9 predominating in AML and older patients, and the authors conclude that this suggests different aetiologies in different age groups.

    The MLL recombinome of acute leukemias in 2017. · Meyer C, Burmeister T, Gröger D, et al. · Leukemia 2018
    What this evidence cannot show

    This is a statement about the KMT2A side, cited here as evidence that breakage in this disease is demonstrably non-uniform along a locus - which is the assumption the intron-length model violates. It is not direct evidence about MLLT1 or MLLT3 breakage.

    Evidence that argues against this (1)
    • Non-uniform breakage on the KMT2A side does not entail non-uniform breakage on the partner side; the two loci are broken by the same event but their local chromatin and repeat content differ, and nobody has published a partner-side cleavage map. Meyer C et al. 2023
  3. E3established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper

    In the recombinome archive, spliced fusions - where the break falls upstream of the partner's exon 1 - account for about 50% of MLLT1 cases (241 of 460) and 2 of 612 MLLT3 cases, and the adult MLLT3 shift towards KMT2A intron 11 is linked to therapy-induced leukaemia.

    The KMT2A recombinome of acute leukemias in 2023. · Meyer C, Larghero P, Almeida Lopes B, et al. · Leukemia 2023
    What this evidence cannot show

    Read in full text from the PMC HTML page (PMC10169636) on 2026-09-20. Independent archive slice from the Hu re-analysis but the same underlying referral series, so the two are not independent confirmations of each other.

    Evidence that argues against this (1)
    • That roughly half of all MLLT1 breaks fall outside the gene entirely is the single largest fact about this locus and it is invisible to any model built on intron lengths, so the intronic comparison necessarily describes a minority of MLL-ENL patients. Hu H et al. 2023
  4. E4established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database

    In hg38, MLLT1 canonical transcript NM_005934.4 spans chr19:6,210,380-6,279,975 on the minus strand with 12 exons and introns of 9,013 / 8,268 / 31,514 / 3,467 / 4,292 / 4,079 / 1,440 / 2,366 / 141 / 317 / 166 bp, and MLLT3 canonical transcript NM_004529.4 spans chr9:20,341,668-20,622,499 on the minus strand with 11 exons and introns of 1,410 / 163,867 / 8,437 / 33,697 / 47,976 / 2,063 / 2,634 / 5,862 / 1,211 / 6,950 bp; in both transcripts exon 1 encodes residues 1-4, exon 2 residues 5-64, exon 3 residues 65-92 and exon 4 residues 93-140.

    What this evidence cannot show

    One canonical RefSeq transcript per gene. Both genes have alternative transcripts, and MLLT3 in particular has an internal promoter driving a YEATS-devoid isoform recorded elsewhere in this graph, so 'the gene structure' here means the structure of NM_004529.4. Intron lengths are genomic distances between exon blocks and take no account of repeat content, chromatin state or topoisomerase-II cleavage preference. The residue mapping is a cumulative-CDS calculation, not an experimental determination.

    Evidence that argues against this (1)
    • Treating intron length as a proxy for breakpoint probability assumes breakage is uniform per base pair, which the same analysis then shows to be false in both genes - so the coordinates are reliable and the model built on them is the part that fails. Meyer C et al. 2018
Connected to